Log in to your Inderes Free account to see all free content on this page.

Immunovia

0.29 SEK

+0.69 %

Less than 1K followers

IMMNOV

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+0.69 %

-6.43 %

-41.89 %

-22.91 %

-31.45 %

-54.30 %

-97.80 %

-99.34 %

-97.27 %

Immunovia operates in the biotechnology industry and focuses on the development of diagnostic tools for the early detection of cancer. The company's research and development is focused on molecular diagnostics and its products are aimed at healthcare institutions and physicians. The business is global with a strong presence in Europe and North America. Immunovia was founded in 2007 and is headquartered in Lund.

Market cap

195.75M SEK

Turnover

1.04M SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

24.2.

2026

Annual report '25

7.5.

2026

Interim report Q1'26

15.5.

2026

General meeting '26

All

Webcasts

Press releases

ShowingAll content types

Regulatory press release11/28/2025, 1:00 PM

Change in number of shares and votes in Immunovia AB (publ)

Press release11/27/2025, 9:30 AM

Carlsquare: Research update Immunovia, Q3 2025: US reimbursement in focus

Press release11/26/2025, 3:05 PM

Immunovia receives final Medicare payment rate for PancreaSure™ test

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release11/26/2025, 8:42 AM

Carlsquare: First impression, Q3 2025: Successful rights issue to fuel launch and reimbursement progress

Regulatory press release11/26/2025, 7:30 AM

Immunovia Publishes Interim Report for July-September 2025

Press release11/24/2025, 1:05 PM

VERIFI Study Published in Peer-Reviewed Journal Current Oncology

Press release11/20/2025, 12:00 PM

INVITATION TO IMMUNOVIA’S Q3 PRESENTATION

Regulatory press release10/29/2025, 5:30 PM

Immunovia carries out a directed issue of shares to guarantors in connection with the completed rights issue

Press release10/27/2025, 1:00 PM

Immunovia's PancreaSure Study Published in Leading Journal Gastroenterology

Press release10/27/2025, 7:00 AM

PancreaSure clinical validation data to be presented at the American Gastroenterology Annual Scientific Meeting

Regulatory press release10/23/2025, 2:00 PM

Immunovia announces outcome of the rights issue

Regulatory press release10/16/2025, 6:30 AM

The last day of trading in subscription rights in Immunovia's rights issue

Press release10/13/2025, 12:05 PM

Immunovia’s Laboratory Receives CAP Accreditation

Press release10/10/2025, 6:30 AM

Immunovia highlights PancreaSure presentation at Inherited Gastrointestinal Cancers Meeting

Regulatory press release10/3/2025, 1:00 PM

Immunovia publishes information document regarding rights issue

Regulatory press release9/29/2025, 12:15 PM

Bulletin from the extraordinary general meeting in Immunovia AB (publ)

Press release9/26/2025, 5:40 AM

Carlsquare: Research update Immunovia: PancreaSure launch in the US is underway

Regulatory press release9/25/2025, 6:50 PM

Immunovia announces final terms of rights issue

Press release9/24/2025, 12:00 PM

PancreaSure™ Demonstrates 88% Sensitivity and 98% Specificity in Interim Analysis of Third Validation Study

Press release9/22/2025, 12:00 PM

Immunovia Secures Control of PancreaSure™ Supply Chain and Achieves Cost Reduction through Licensing Agreement

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.